Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Reduce” by Analysts
Head-To-Head Review: Pliant Therapeutics (NASDAQ:PLRX) versus Dermata Therapeutics (NASDAQ:DRMA)
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
Stock Picks From Seeking Alpha's February 2026 New Analysts
Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Short Interest Up 21.0% in January
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Pliant Therapeutics Provides Update on BEACON-IPF
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims - On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
Pliant Therapeutics: An Activist On Deck
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRX